Last Update 17 May 26
Fair value Increased 0.73%532926: Upcoming Board Actions And Updated Assumptions Will Support Earnings Visibility
Analysts have slightly increased their fair value estimate for Jyothy Labs to ₹289 from ₹286.91, reflecting updates to assumptions on discount rate, revenue growth, profit margins, and future P/E multiples.
What's in the News
- A board meeting is scheduled for May 04, 2026, at 11:00 Indian Standard Time to review and approve the audited financial results for the quarter and year ended March 31, 2026, including the auditors' reports. (Key Developments)
- The May 04, 2026, board meeting agenda also includes considering a dividend recommendation on equity shares for the 2025-26 financial year. (Key Developments)
- The board plans to consider convening the 2026 Annual General Meeting and address other corporate matters at the May 04, 2026, meeting. (Key Developments)
- An additional board meeting is scheduled for May 09, 2026, with details not specified in the available summary. (Key Developments)
Valuation Changes
- Fair Value Estimate revised slightly higher from ₹286.91 to ₹289.00.
- Discount Rate adjusted marginally from 12.48% to 12.51%.
- Revenue Growth updated from 7.83% to 7.54%.
- Net Profit Margin reset from 12.73% to 11.55%.
- Future P/E moved from 32.09x to 34.92x.
Key Takeaways
- Growth in digital channels and premium product innovation is expected to boost margins, strengthen brand presence, and drive broader geographic expansion.
- Operational improvements and strategic focus on high-demand segments should lift profitability and ensure sustainable long-term revenue growth.
- Intense competition, weak urban demand, persistent input cost pressures, and sluggish innovation threaten Jyothy Labs' margins, growth prospects, and long-term profitability.
Catalysts
About Jyothy Labs- Engages in the manufacture and marketing of fabric care, dishwashing, personal care, and household insecticides products in India and internationally.
- The expected recovery in rural and eventual urban demand, supported by above-normal monsoons, easing inflation, and recent government fiscal measures, should expand the consumer base for Jyothy Labs' core categories, setting the stage for accelerated revenue growth from H2 FY26 onwards.
- Ongoing double-digit growth in modern trade, e-commerce, and quick commerce leverages scalable digital channels, allowing Jyothy Labs to improve distribution efficiency, capture new geographies, and potentially enhance net margins as these channels grow in mix.
- Strategic investments in premium product innovation (e.g. new launches in fabric conditioners and beauty soaps, expansion of premium brands like Henko and Ujala) are likely to increase pricing power, strengthen brand equity, and support margin expansion over the medium term.
- Initiatives to turn around the Household Insecticides segment (targeting profitability by H2 FY27) and operational efficiency improvements in manufacturing are set to reduce segment losses and drive operating leverage, lifting overall earnings growth.
- If long-term trends in hygiene and personal care consumption persist amid rising health awareness and organized sector penetration, Jyothy Labs stands to gain sustainable topline expansion and improved market share, strengthening revenue visibility over multiple years.
Jyothy Labs Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Jyothy Labs's revenue will grow by 7.5% annually over the next 3 years.
- Analysts assume that profit margins will increase from 11.1% today to 11.5% in 3 years time.
- Analysts expect earnings to reach ₹4.3 billion (and earnings per share of ₹11.78) by about May 2029, up from ₹3.3 billion today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as ₹3.9 billion.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 35.0x on those 2029 earnings, up from 24.2x today. This future PE is greater than the current PE for the IN Household Products industry at 16.6x.
- Analysts expect the number of shares outstanding to grow by 0.09% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 12.51%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- Sustained competitive intensity across all core categories (Fabric Care, Dishwashing, Personal Care) is driving price cuts, higher promotions, and grammage increases, all of which compress gross margins and risk further margin erosion if competitive pressures persist, directly impacting earnings and profitability.
- Prolonged underperformance and continued losses in the Household Insecticides segment remain a material drag on overall profitability; management's hope to turn this business around by FY27 is uncertain, and failure to do so could prevent margin recovery and reduce group net earnings.
- Urban demand remains fragile, with traditional trade (a key Jyothy Labs distribution channel) underperforming and facing outlet closures, while growth in e-commerce and modern trade is partly cannibalizing rather than genuinely expanding incremental consumption, which may constrain long-term revenue growth if urban consumption patterns do not rebound strongly.
- Gross margin contraction (down 330 bps year-on-year) due to ongoing input cost pressures (key raw materials, delayed cost pass-through) and intense promotional activity may persist if crude/derivative costs remain volatile or if competitive promotional activity escalates, limiting potential for net margin expansion and earnings growth.
- The company's innovation pipeline and category development efforts are described as modest and slow-moving ("slow and steady," "early days"), reflecting risk that Jyothy Labs may not premiumize or diversify fast enough to offset stagnation in legacy brands-constraining future revenue streams and weakening long-term pricing power.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of ₹289.0 for Jyothy Labs based on their expectations of its future earnings growth, profit margins and other risk factors.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of ₹340.0, and the most bearish reporting a price target of just ₹245.0.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be ₹37.5 billion, earnings will come to ₹4.3 billion, and it would be trading on a PE ratio of 35.0x, assuming you use a discount rate of 12.5%.
- Given the current share price of ₹219.2, the analyst price target of ₹289.0 is 24.2% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Jyothy Labs?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.